Achilles Therapeutics plc Key Executives
This section highlights Achilles Therapeutics plc's key executives, including their titles and compensation details.
Find Contacts at Achilles Therapeutics plc
(Showing 0 of )
Achilles Therapeutics plc Earnings
This section highlights Achilles Therapeutics plc's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Achilles Therapeutics plc, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $4.73M | $3.69M | $3.29M | $778.00K | $303.25K |
| Gross Profit | $-4.73M | $-3.69M | $-3.29M | $-778.00K | $-303.25K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $67.65M | $57.26M | $42.22M | $22.63M | $9.07M |
| General and Administrative Expenses | $17.01M | $21.12M | $21.97M | $11.10M | $4.70M |
| Selling and Marketing Expenses | $-4.67M | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $12.34M | $21.12M | $21.97M | $11.10M | $4.70M |
| Other Expenses | $-9.40M | $7.32M | $3.13M | $531.00K | $-215.00K |
| Operating Expenses | $75.25M | $78.38M | $64.19M | $33.73M | $13.78M |
| Cost and Expenses | $75.25M | $78.38M | $64.19M | $33.73M | $13.78M |
| Interest Income | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $4.73M | $3.69M | $3.29M | $778.00K | $303.25K |
| EBITDA | $-70.44M | $-78.38M | $-57.77M | $-32.95M | $-13.47M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-75.25M | $-78.38M | $-64.19M | $-33.73M | $-13.78M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $6.08M | $7.32M | $3.13M | $531.00K | $-215.00K |
| Income Before Tax | $-69.17M | $-71.06M | $-61.06M | $-33.20M | $-13.99M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $491.00K | $111.00K | $37.00K | $3.00K | $130.14K |
| Net Income | $-69.67M | $-71.18M | $-61.10M | $-33.20M | $-13.99M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-1.74 | $-1.82 | $-2.13 | $-0.82 | $-8.52 |
| EPS Diluted | $-1.74 | $-1.82 | $-2.13 | $-0.82 | $-8.52 |
| Weighted Average Shares Outstanding | 39.97M | 39.14M | 28.65M | 40.62M | 1.64M |
| Weighted Average Shares Outstanding Diluted | 39.97M | 39.14M | 28.65M | 40.62M | 1.64M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | January 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $580.00K | $- | $- | $- |
| Cost of Revenue | $- | $1.18M | $1.18M | $1.16M | $1.20M | $1.30M | $- | $837.23K | $892.33K | $892.17K | $1.05M | $838.03K | $895.96K | $798.44K | $- | $- | $290.00K | $- | $- | $- |
| Gross Profit | $- | $-1.18M | $-1.18M | $-1.16M | $-1.20M | $-1.30M | $- | $-837.23K | $-892.33K | $-892.17K | $-1.05M | $-838.03K | $-895.96K | $-798.44K | $- | $- | $290.00K | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 50.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $16.40M | $13.63M | $10.13M | $16.03M | $14.71M | $13.77M | $13.87M | $18.88M | $10.60M | $14.78M | $13.01M | $11.81M | $10.70M | $10.84M | $8.88M | $8.96M | $5.29M | $4.55M | $3.83M | $2.75M |
| General and Administrative Expenses | $4.02M | $4.16M | $4.16M | $3.62M | $4.38M | $4.32M | $4.68M | $3.96M | $5.44M | $5.77M | $5.96M | $6.65M | $5.04M | $5.45M | $4.83M | $3.96M | $3.01M | $2.40M | $1.74M | $1.69M |
| Selling and Marketing Expenses | $- | $- | $-1.18M | $-1.13M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.02M | $4.16M | $2.98M | $2.50M | $4.38M | $4.32M | $4.68M | $3.96M | $5.44M | $5.77M | $5.96M | $6.65M | $5.04M | $5.45M | $4.83M | $3.96M | $3.01M | $2.40M | $1.74M | $1.69M |
| Other Expenses | $- | $- | $2.00M | $1.39M | $2.39M | $1.21M | $1.09M | $-1.18M | $3.60M | $3.27M | $1.63M | $226.00K | $2.81M | $146.00K | $-45.00K | $2.00K | $90.00K | $87.00K | $352.00K | $-16.73M |
| Operating Expenses | $20.42M | $17.80M | $13.11M | $18.53M | $19.10M | $18.09M | $18.55M | $22.83M | $16.03M | $20.55M | $18.97M | $18.46M | $15.74M | $16.29M | $13.71M | $12.92M | $8.30M | $6.94M | $5.57M | $4.56M |
| Cost and Expenses | $20.42M | $17.80M | $14.29M | $19.68M | $19.10M | $18.09M | $18.55M | $22.83M | $16.03M | $20.55M | $18.97M | $18.46M | $15.74M | $16.29M | $13.71M | $12.92M | $8.30M | $6.94M | $5.57M | $4.56M |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $1.18M | $- | $- | $- | $- | $- | $- | $45.00K | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $1.18M | $1.18M | $1.16M | $1.20M | $1.30M | $1.11M | $837.23K | $892.33K | $892.17K | $1.05M | $838.03K | $895.96K | $798.44K | $789.00K | $399.00K | $169.00K | $107.00K | $97.00K | $99.00K |
| EBITDA | $-20.42M | $-16.62M | $-13.12M | $-18.27M | $-17.89M | $-16.84M | $-17.45M | $-23.36M | $-15.14M | $-19.63M | $-17.92M | $-17.85M | $-14.91M | $-15.46M | $-12.92M | $-12.52M | $-8.13M | $-6.83M | $-5.47M | $-4.34M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1431.03% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-20.42M | $-17.80M | $-14.29M | $-19.68M | $-19.10M | $-18.09M | $-18.55M | $-22.83M | $-16.03M | $-20.55M | $-18.97M | $-18.46M | $-15.74M | $-16.29M | $-13.71M | $-12.92M | $-8.30M | $-6.94M | $-5.57M | $-4.43M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1431.03% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $817.00K | $1.43M | $2.00M | $1.39M | $2.39M | $1.21M | $1.09M | $-1.18M | $3.60M | $3.27M | $1.63M | $226.00K | $2.81M | $146.00K | $-45.00K | $2.00K | $90.00K | $87.00K | $352.00K | $-123.00K |
| Income Before Tax | $-19.60M | $-16.37M | $-12.29M | $-18.28M | $-16.71M | $-16.88M | $-17.46M | $-24.02M | $-12.44M | $-17.27M | $-17.34M | $-18.23M | $-12.93M | $-16.14M | $-13.75M | $-12.92M | $-8.21M | $-6.86M | $-5.21M | $-4.56M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1415.52% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $-5.00K | $8.00K | $-22.99K | $509.39K | $-24.00K | $-34.00K | $44.00K | $41.00K | $41.00K | $14.00K | $15.00K | $-4.00K | $16.00K | $13.00K | $12.00K | $3.00K | $750 | $750 | $750 | $750 |
| Net Income | $-19.59M | $-16.38M | $-12.27M | $-18.79M | $-16.68M | $-16.85M | $-17.51M | $-24.06M | $-12.48M | $-17.29M | $-17.36M | $-18.23M | $-12.95M | $-16.16M | $-13.77M | $-12.92M | $-8.21M | $-6.86M | $-5.21M | $-4.56M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1415.52% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.48 | $-0.41 | $-0.30 | $-0.47 | $-0.42 | $-0.42 | $-0.44 | $-0.61 | $-0.32 | $-0.44 | $-0.45 | $-0.64 | $-0.34 | $-0.45 | $-8.38 | $-0.32 | $-5.00 | $-4.17 | $-3.18 | $-6.30 |
| EPS Diluted | $-0.48 | $-0.41 | $-0.30 | $-0.47 | $-0.42 | $-0.42 | $-0.44 | $-0.61 | $-0.32 | $-0.44 | $-0.45 | $-0.64 | $-0.34 | $-0.45 | $-8.38 | $-0.32 | $-5.00 | $-4.17 | $-3.18 | $-6.29 |
| Weighted Average Shares Outstanding | 40.43M | 40.36M | 40.28M | 40.19M | 40.07M | 39.90M | 39.73M | 39.52M | 39.31M | 39.10M | 38.89M | 28.65M | 38.26M | 35.68M | 1.64M | 40.62M | 1.64M | 1.64M | 1.64M | 724.00K |
| Weighted Average Shares Outstanding Diluted | 40.43M | 40.36M | 40.28M | 40.19M | 40.07M | 39.90M | 39.73M | 39.52M | 39.31M | 39.10M | 38.89M | 28.65M | 38.26M | 35.68M | 1.64M | 40.62M | 1.64M | 1.64M | 1.64M | 724.42K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $131.54M | $173.34M | $266.32M | $177.85M | $97.59M |
| Short Term Investments | $1 | $- | $- | $- | $265 |
| Cash and Short Term Investments | $131.54M | $173.34M | $266.32M | $177.85M | $97.59M |
| Net Receivables | $10.35M | $16.00M | $11.17M | $7.34M | $4.49M |
| Inventory | $1 | $4.62M | $5.13M | $1.76M | $504.00K |
| Other Current Assets | $3.74M | $7.24M | $7.26M | $2.61M | $981.00K |
| Total Current Assets | $145.63M | $196.58M | $284.75M | $187.80M | $103.06M |
| Property Plant Equipment Net | $13.54M | $20.48M | $28.79M | $28.11M | $2.11M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $1 | $-33.00K | $-33.00K | $- | $- |
| Long Term Investments | $33.00K | $33.00K | $33.00K | $- | $- |
| Tax Assets | $41.00K | $251.00K | $26.00K | $4.00K | $- |
| Other Non-Current Assets | $2.21M | $3.05M | $3.54M | $3.01M | $34.00K |
| Total Non-Current Assets | $15.82M | $23.78M | $32.36M | $31.12M | $2.14M |
| Other Assets | $- | $- | $- | $- | $0 |
| Total Assets | $161.46M | $220.36M | $317.11M | $218.92M | $105.20M |
| Account Payables | $5.63M | $5.19M | $3.72M | $6.31M | $902.00K |
| Short Term Debt | $3.54M | $4.19M | $4.48M | $3.71M | $487.00K |
| Tax Payables | $- | $326.00K | $- | $7.00K | $- |
| Deferred Revenue | $- | $- | $9.64M | $5.23M | $1.79M |
| Other Current Liabilities | $7.83M | $8.29M | $10.91M | $6.59M | $2.47M |
| Total Current Liabilities | $17.00M | $17.99M | $19.11M | $16.62M | $3.86M |
| Long Term Debt | $1.08M | $4.39M | $7.78M | $12.27M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.01M | $933.00K | $691.00K | $652.00K | $- |
| Total Non-Current Liabilities | $2.09M | $5.32M | $8.47M | $12.92M | $- |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $19.09M | $23.31M | $27.58M | $29.55M | $3.86M |
| Preferred Stock | $- | $- | $- | $134.00K | $79.00K |
| Common Stock | $182.00K | $54.00K | $54.00K | $25.00K | $14.00K |
| Retained Earnings | $-259.95M | $-190.29M | $-119.11M | $-58.01M | $-24.81M |
| Accumulated Other Comprehensive Income Loss | $-13.07M | $-21.70M | $6.64M | $12.32M | $8.11M |
| Other Total Stockholders Equity | $415.21M | $408.97M | $401.95M | $234.92M | $117.96M |
| Total Stockholders Equity | $142.37M | $197.04M | $289.53M | $189.37M | $101.35M |
| Total Equity | $142.37M | $197.04M | $289.53M | $189.37M | $101.35M |
| Total Liabilities and Stockholders Equity | $161.46M | $220.36M | $317.11M | $218.92M | $105.20M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $161.46M | $220.36M | $317.11M | $218.92M | $105.20M |
| Total Investments | $33.00K | $33.00K | $33.00K | $- | $265 |
| Total Debt | $4.62M | $8.58M | $12.26M | $15.98M | $487.00K |
| Net Debt | $-126.92M | $-164.76M | $-254.06M | $-161.87M | $-97.11M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | January 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $86.05M | $95.11M | $112.32M | $131.54M | $140.14M | $143.71M | $158.46M | $173.34M | $179.89M | $201.59M | $236.93M | $266.32M | $281.88M | $299.32M | $159.26M | $177.85M | $71.60M | $79.47M | $-97.86M | $97.59M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $195.72M | $265.00K |
| Cash and Short Term Investments | $86.05M | $95.11M | $112.32M | $131.54M | $140.14M | $143.71M | $158.46M | $173.34M | $179.89M | $201.59M | $236.93M | $266.32M | $281.88M | $299.32M | $159.26M | $177.85M | $71.60M | $79.47M | $97.86M | $97.86M |
| Net Receivables | $21.79M | $- | $15.73M | $10.35M | $9.60M | $23.03M | $- | $16.00M | $- | $17.13M | $14.46M | $11.17M | $- | $11.96M | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $1 | $-9.60M | $-23.03M | $- | $4.62M | $-10.71M | $5.96M | $4.25M | $5.13M | $6.27M | $8.10M | $3.92M | $1.76M | $-1.83M | $-1.83M | $-2.49M | $-1.83M |
| Other Current Assets | $3.79M | $22.71M | $3.37M | $3.74M | $5.76M | $31.50M | $26.80M | $7.24M | $4.84M | $8.85M | $7.43M | $7.26M | $16.40M | $9.12M | $14.06M | $9.95M | $5.53M | $4.76M | $- | $5.20M |
| Total Current Assets | $111.62M | $117.82M | $131.43M | $145.63M | $155.49M | $175.21M | $185.26M | $196.58M | $198.69M | $227.58M | $259.05M | $284.75M | $298.28M | $320.40M | $173.32M | $187.80M | $77.13M | $84.24M | $97.86M | $103.06M |
| Property Plant Equipment Net | $9.23M | $11.12M | $12.07M | $13.54M | $16.66M | $19.32M | $19.02M | $20.48M | $25.89M | $27.10M | $29.45M | $28.79M | $28.32M | $29.85M | $29.63M | $28.11M | $17.62M | $13.49M | $7.03M | $2.11M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $1 | $-1 | $-33.00K | $-33.00K | $-33.00K | $-33.00K | $-33.00K | $-33.00K | $-33.00K | $-33.00K | $-33.00K | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $53.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $41.00K | $- | $41.00K | $41.00K | $185.00K | $185.00K | $185.00K | $251.00K | $26.00K | $26.00K | $26.00K | $26.00K | $4.00K | $4.00K | $4.00K | $4.00K | $1.00K | $1.00K | $1.00K | $1.00K |
| Other Non-Current Assets | $1.78M | $2.20M | $2.17M | $2.21M | $3.00M | $3.19M | $3.17M | $3.05M | $2.75M | $3.02M | $3.67M | $3.54M | $3.40M | $3.24M | $3.15M | $3.01M | $1.81M | $1.75M | $-104.89M | $33.00K |
| Total Non-Current Assets | $11.05M | $13.37M | $14.31M | $15.82M | $19.85M | $22.70M | $22.37M | $23.78M | $28.66M | $30.14M | $33.14M | $32.36M | $31.72M | $33.09M | $32.78M | $31.12M | $19.43M | $15.24M | $-97.86M | $2.14M |
| Other Assets | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $54.73M | $- |
| Total Assets | $122.68M | $131.19M | $145.74M | $161.46M | $175.34M | $197.91M | $207.63M | $220.36M | $227.35M | $257.72M | $292.19M | $317.11M | $330.00M | $353.49M | $206.10M | $218.92M | $96.56M | $99.48M | $54.73M | $105.20M |
| Account Payables | $4.25M | $2.87M | $3.31M | $5.63M | $5.35M | $6.89M | $7.65M | $5.19M | $7.52M | $6.65M | $4.04M | $3.72M | $2.46M | $6.05M | $1.79M | $6.31M | $1.06M | $1.22M | $1.58M | $902.00K |
| Short Term Debt | $3.62M | $4.21M | $3.63M | $3.54M | $4.62M | $4.66M | $4.04M | $4.19M | $4.04M | $4.48M | $4.67M | $4.48M | $4.40M | $4.66M | $4.61M | $3.71M | $2.62M | $2.10M | $- | $487.00K |
| Tax Payables | $- | $- | $- | $- | $- | $7.00K | $304.00K | $326.00K | $59.00K | $18.00K | $15.00K | $- | $36.00K | $19.00K | $19.00K | $7.00K | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $-3.31M | $-5.63M | $- | $- | $- | $- | $- | $- | $- | $9.64M | $6.59M | $6.30M | $7.42M | $5.23M | $- | $- | $- | $- |
| Other Current Liabilities | $10.60M | $7.22M | $6.71M | $7.83M | $8.21M | $7.57M | $5.96M | $8.29M | $7.45M | $8.72M | $9.13M | $10.91M | $8.47M | $7.88M | $8.65M | $6.59M | $4.63M | $3.76M | $2.58M | $2.47M |
| Total Current Liabilities | $18.47M | $14.29M | $13.65M | $17.00M | $18.18M | $19.12M | $17.95M | $17.99M | $19.06M | $19.87M | $17.85M | $19.11M | $15.37M | $18.61M | $15.06M | $16.62M | $8.31M | $7.07M | $4.16M | $3.86M |
| Long Term Debt | $- | $258.00K | $584.00K | $1.08M | $2.73M | $3.97M | $3.56M | $4.39M | $4.95M | $5.64M | $7.21M | $7.78M | $8.88M | $10.24M | $11.33M | $12.27M | $8.68M | $9.05M | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.07M | $1.16M | $1.16M | $1.01M | $941.00K | $974.00K | $954.00K | $933.00K | $726.00K | $621.00K | $671.00K | $691.00K | $643.00K | $659.00K | $659.00K | $652.00K | $429.00K | $- | $3.23M | $- |
| Total Non-Current Liabilities | $1.07M | $1.42M | $1.74M | $2.09M | $3.67M | $4.95M | $4.52M | $5.32M | $5.68M | $6.26M | $7.88M | $8.47M | $9.52M | $10.90M | $11.99M | $12.92M | $9.11M | $9.05M | $3.23M | $3.23M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-3.23M |
| Total Liabilities | $19.54M | $15.71M | $15.39M | $19.09M | $21.85M | $24.06M | $22.46M | $23.31M | $24.73M | $26.13M | $25.73M | $27.58M | $24.89M | $29.52M | $27.05M | $29.55M | $17.42M | $16.12M | $7.39M | $3.86M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $128.00K | $128.00K | $- | $128.00K | $- | $134.00K | $134.00K | $1.00K | $- | $79.00K | $79.00K |
| Common Stock | $54.00K | $182.00K | $182.00K | $182.00K | $54.00K | $54.00K | $54.00K | $54.00K | $54.00K | $54.00K | $54.00K | $54.00K | $54.00K | $54.00K | $6.00K | $25.00K | $6.25K | $1.00K | $6.25K | $14.00K |
| Retained Earnings | $-308.20M | $-288.61M | $-272.23M | $-259.95M | $-241.32M | $-224.64M | $-207.79M | $-190.29M | $-166.23M | $-153.75M | $-136.47M | $-119.11M | $-100.88M | $-87.93M | $-71.78M | $-58.01M | $-45.09M | $-36.88M | $-14.50M | $-24.81M |
| Accumulated Other Comprehensive Income Loss | $-7.94M | $-14.02M | $-14.21M | $-13.07M | $-19.19M | $-13.90M | $-17.72M | $-21.70M | $-38.49M | $-20.34M | $-1.04M | $6.64M | $5.75M | $13.46M | $14.38M | $12.32M | $5.02M | $1.52M | $101.27M | $8.11M |
| Other Total Stockholders Equity | $419.23M | $417.91M | $416.60M | $415.21M | $413.81M | $412.33M | $410.63M | $408.97M | $407.28M | $405.50M | $403.78M | $401.95M | $400.06M | $398.39M | $236.31M | $234.92M | $119.20M | $118.72M | $- | $117.96M |
| Total Stockholders Equity | $103.14M | $115.47M | $130.35M | $142.37M | $153.49M | $173.84M | $185.17M | $197.04M | $202.62M | $231.59M | $266.45M | $289.53M | $305.11M | $323.97M | $179.05M | $189.37M | $79.14M | $83.35M | $101.35M | $101.35M |
| Total Equity | $103.14M | $115.47M | $130.35M | $142.37M | $153.49M | $173.84M | $185.17M | $197.04M | $202.62M | $231.59M | $266.45M | $289.53M | $305.11M | $323.97M | $179.05M | $189.37M | $79.14M | $83.35M | $101.35M | $101.35M |
| Total Liabilities and Stockholders Equity | $122.68M | $131.19M | $145.74M | $161.46M | $175.34M | $197.91M | $207.63M | $220.36M | $227.35M | $257.72M | $292.19M | $317.11M | $330.00M | $353.49M | $206.10M | $218.92M | $96.56M | $99.48M | $101.35M | $105.20M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $122.68M | $131.19M | $145.74M | $161.46M | $175.34M | $197.91M | $207.63M | $220.36M | $227.35M | $257.72M | $292.19M | $317.11M | $330.00M | $353.49M | $206.10M | $218.92M | $96.56M | $99.48M | $101.35M | $105.20M |
| Total Investments | $- | $53.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K | $- | $- | $- | $- | $- | $195.72M | $265.00K |
| Total Debt | $3.62M | $4.46M | $4.21M | $4.62M | $7.35M | $8.63M | $7.60M | $8.58M | $8.99M | $10.12M | $11.88M | $12.26M | $13.28M | $14.90M | $15.94M | $15.98M | $8.68M | $9.05M | $4.00M | $4.00M |
| Net Debt | $-82.43M | $-90.65M | $-108.11M | $-126.92M | $-132.79M | $-135.08M | $-150.86M | $-164.76M | $-170.90M | $-191.47M | $-225.05M | $-254.06M | $-268.60M | $-284.41M | $-143.32M | $-161.87M | $-62.92M | $-70.42M | $101.85M | $-93.60M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-69.94M | $-71.18M | $-61.10M | $-33.20M | $-13.99M |
| Depreciation and Amortization | $4.71M | $3.69M | $3.29M | $772.00K | $302.00K |
| Deferred Income Tax | $- | $- | $159.00K | $- | $14.00K |
| Stock Based Compensation | $6.36M | $7.02M | $6.32M | $2.99M | $719.00K |
| Change in Working Capital | $10.41M | $-5.96M | $-7.93M | $3.00M | $-1.18M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $1.91M | $-2.57M | $5.26M | $548.00K |
| Other Working Capital | $10.41M | $-7.86M | $-5.36M | $-2.25M | $-1.73M |
| Other Non Cash Items | $7.03K | $6.88M | $-18.00K | $1.18M | $-9.00K |
| Net Cash Provided by Operating Activities | $-48.45M | $-59.53M | $-59.28M | $-25.25M | $-14.14M |
| Investments in Property Plant and Equipment | $-1.10M | $-7.51M | $-7.63M | $-11.85M | $-942.00K |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-7.51M | $-7.63M | $- | $- |
| Net Cash Used for Investing Activities | $-1.10M | $-7.51M | $-7.63M | $-11.85M | $-942.00K |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $9.00K | $1.00K | $160.74M | $114.59M | $94.01M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $35 | $- | $160.75M | $113.70M | $93.23M |
| Net Cash Used Provided by Financing Activities | $9.00K | $1.00K | $160.75K | $113.70M | $93.62M |
| Effect of Forex Changes on Cash | $7.74M | $-25.93M | $-5.33M | $3.65M | $8.37M |
| Net Change in Cash | $-41.80M | $-92.98M | $88.50M | $80.25M | $86.91M |
| Cash at End of Period | $131.57M | $173.37M | $266.35M | $177.85M | $97.59M |
| Cash at Beginning of Period | $173.37M | $266.35M | $177.85M | $97.59M | $10.68M |
| Operating Cash Flow | $-48.45M | $-59.53M | $-59.28M | $-25.25M | $-14.14M |
| Capital Expenditure | $-1.10M | $-7.51M | $-7.63M | $-11.85M | $-942.00K |
| Free Cash Flow | $-49.55M | $-67.05M | $-66.92M | $-37.10M | $-15.08M |
Cash Flow Charts
| Breakdown | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | January 31, 2020 | September 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-16.38K | $-12.27M | $-18.79M | $-16.59M | $-16.85K | $-17.51M | $-24.24M | $-12.37M | $-17.29M | $-17.36M | $-18.23M | $-12.95M | $-16.16M | $-13.77M | $-12.92M | $-8.21K | $-6.86K | $-5.21M | $-4.56K | $-2.35K |
| Depreciation and Amortization | $1.18M | $1.18M | $1.16M | $1.20M | $1.25K | $1.11M | $837.23K | $892.33K | $916.00K | $1.05M | $837.00K | $832.00K | $830.00K | $789.00K | $399.00K | $169 | $107 | $97.00K | $99 | $81 |
| Deferred Income Tax | $- | $- | $-3.71M | $-2.40M | $- | $- | $-3.36M | $-3.43M | $- | $- | $155.00K | $4.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $1.31M | $1.39M | $1.40M | $1.61K | $1.70K | $1.65M | $1.69M | $1.65M | $1.72M | $1.96M | $1.76M | $1.73M | $1.44M | $1.38M | $1.84M | $490 | $326 | $338.00K | $355 | $161 |
| Change in Working Capital | $-3.04K | $-7.80M | $2.01M | $14.89M | $-2.56K | $-3.00M | $-4.74M | $6.85M | $-2.20M | $-5.92M | $1.32M | $1.58M | $-4.67M | $-6.16M | $1.91M | $914 | $1.90K | $-1.92M | $-974 | $-1.95K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $-1.94M | $-146.00K | $- | $- | $2.42M | $-2.67M | $1.37M | $2.78M | $423.00K | $1.30M | $-3.54M | $4.26M | $-4.59M | $4.89M | $1.31M | $1.31M | $173.00K | $1.31M | $137.00K |
| Other Working Capital | $-3.04K | $-7.80M | $2.15M | $14.89M | $-2.56K | $65.00K | $-2.08M | $5.49M | $-4.98M | $-6.34M | $22.00K | $5.12M | $-8.94M | $-1.56M | $-2.98M | $914 | $1.90K | $-2.09M | $-974 | $-1.95K |
| Other Non Cash Items | $-19.80M | $3.75M | $3.72M | $3.97M | $-954 | $-122.00K | $10.10M | $3.45M | $440.00K | $-376.00K | $-137.00K | $-295.00K | $-113.00K | $527.00K | $418.00K | $13 | $818 | $128.00K | $-452 | $671 |
| Net Cash Provided by Operating Activities | $-17.33M | $-17.50M | $-14.23M | $1.07M | $-17.41K | $-17.85M | $-19.72M | $-2.96M | $-16.41M | $-20.64M | $-14.29M | $-9.10M | $-18.68M | $-17.22M | $-8.36M | $-6.62K | $-3.70K | $-6.57M | $-5.53K | $-3.38K |
| Investments in Property Plant and Equipment | $-36 | $-694.60K | $-45.61K | $-61.38K | $-537 | $-454.00K | $-2.07M | $-1.86M | $-1.74M | $-1.86M | $-2.00M | $-1.22M | $-2.04M | $-2.38M | $-5.98M | $-4.54K | $-713 | $-619.00K | $-397 | $-480 |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-35.96K | $- | $- | $- | $- | $- | $-7.51M | $- | $- | $- | $-7.63M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-36.00K | $-694.60K | $-45.61K | $-61.38K | $-537 | $-454.00K | $-2.07M | $-1.86M | $-1.74M | $-1.86M | $-2.00M | $-1.22M | $-2.04M | $-2.38M | $-5.98M | $-4.54K | $-713 | $-619.00K | $-397 | $-480 |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $4 | $5.00K | $-5 | $8.03K | $- | $- | $10 | $990 | $- | $- | $-389.58K | $60.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $3 | $- | $- | $- | $1.00K | $- | $10 | $- | $- | $60.00K | $- | $161.61M | $-914.00K | $113.90M | $28.43M | $28.43M | $-196.00K | $182 | $80.19K |
| Net Cash Used Provided by Financing Activities | $4 | $5.00K | $-5 | $8.03K | $- | $1 | $10 | $990 | $- | $- | $-389.58K | $60 | $161.61K | $-914 | $113.90M | $28.43M | $28.43M | $-196.00K | $182 | $80.19K |
| Effect of Forex Changes on Cash | $153 | $-1.02M | $5.64M | $-4.52K | $3.20K | $3.43M | $14.80M | $-16.66M | $-17.19M | $-6.89M | $734.00K | $-7.15M | $-842.00K | $1.93M | $6.68M | $3.29K | $-142 | $-6.18M | $7.46K | $915 |
| Net Change in Cash | $-17.19M | $-19.22M | $-8.60M | $-3.57M | $-14.75K | $-14.88M | $-6.55M | $-21.70M | $-35.34M | $-29.39M | $-15.56M | $-17.41M | $140.06M | $-18.59M | $106.25M | $-7.87K | $-4.56K | $-13.56M | $1.72K | $77.24K |
| Cash at End of Period | $95.16K | $112.32M | $131.54M | $140.14M | $143.74K | $158.49M | $173.34M | $179.89M | $201.63M | $236.96M | $266.35M | $281.91M | $299.32M | $159.26M | $177.85M | $71.60K | $79.47K | $84.03M | $97.59K | $95.88K |
| Cash at Beginning of Period | $112.36K | $131.54M | $140.14M | $143.71M | $158.49K | $173.37M | $179.89M | $201.59M | $236.96M | $266.35M | $281.91M | $299.32M | $159.26M | $177.85M | $71.60M | $79.47K | $84.03K | $97.59M | $95.88K | $18.63K |
| Operating Cash Flow | $-17.31K | $-17.50M | $-14.23M | $1.07M | $-17.41K | $-17.85M | $-19.72M | $-2.96M | $-16.41M | $-20.64M | $-14.29M | $-9.10M | $-18.68M | $-17.22M | $-8.36M | $-6.62K | $-3.70K | $-6.57M | $-5.53K | $-3.38K |
| Capital Expenditure | $-36 | $-694.60K | $-45.61K | $-61.38K | $-537 | $-454.00K | $-2.07M | $-1.86M | $-1.74M | $-1.86M | $-2.00M | $-1.22M | $-2.04M | $-2.38M | $-5.98M | $-4.54K | $-713 | $-619.00K | $-397 | $-480 |
| Free Cash Flow | $-17.34K | $-18.19M | $-14.27M | $1.01M | $-17.95K | $-18.31M | $-21.79M | $-4.83M | $-18.14M | $-22.50M | $-16.29M | $-10.32M | $-20.71M | $-19.60M | $-14.34M | $-11.16K | $-4.42K | $-7.19M | $-5.93K | $-3.86K |
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
$1.48
Stock Price
$60.83M
Market Cap
204
Employees
London, None
Location
Revenue (FY 2023)
$-
0.0% YoY
Net Income (FY 2023)
$-69.67M
2.1% YoY
EPS (FY 2023)
$-1.74
4.4% YoY
Free Cash Flow (FY 2023)
$-49.55M
26.1% YoY
Profitability
Gross Margin
0.0%
Net Margin
0.0%
ROE
-48.9%
ROA
-43.1%
Valuation
P/E Ratio
-0.51
P/S Ratio
0.00
EV/EBITDA
1.30
Market Cap
$60.83M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-48.45M
18.6% YoY
Free Cash Flow
$-49.55M
26.1% YoY
Balance Sheet Summary
Total Assets
$161.46M
-26.7% YoY
Total Debt
$4.62M
46.2% YoY
Shareholder Equity
$142.37M
-29.3% YoY
Dividend Overview
No Dividend Data
Achilles Therapeutics plc doesn't currently pay dividends.
Achilles Therapeutics plc Dividends
Explore Achilles Therapeutics plc's dividend history, including dividend yield, payout ratio, and historical payments.
Achilles Therapeutics plc News
Read the latest news about Achilles Therapeutics plc, including recent articles, headlines, and updates.
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") approved the Company's request to transfer the listing of the Company's American Depositary Shares (the "ADSs") from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is expected to take effect at the opening of business on November 19, 2024.
Achilles Therapeutics Announces Strategic Update
–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice– LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials.
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company's operations are not affected by the receipt of the Notice Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company's operations are not affected by the receipt of the Notice
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 2024 – – Strong cash position of $112.3 million supports operations through 2025 – LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and recent business highlights. “Just after the close of the first quarter, we shared the interim Phase I/IIa data from our ongoing CHIRON and THETIS TIL-based cNeT clinical trials which have given us important mechanistic learnings about the factors driving durable engraftment and immune evasion at an antigen level.
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – Strong cash position of $131.5 million supports operations through 2025 – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights. “In 2023, we made important progress on the optimization of our VELOS™ manufacturing process with a significant improvement in cNeT doses delivered and are developing our understanding of the relationship between host conditioning and the engraftment of infused cNeT.
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells (cNeT) from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and the THETIS study in recurrent or metastatic malignant melanoma. The update includes data from 18 patients across CHIRON (n=12) and THETIS (n=6) dosed since the previous interim update in December 2022, with two CHIRON patients and one THETIS patient having received enhanced chemo-conditioning and IL-2 dosing aligned to standard tumor infiltrating lymphocyte (TIL) therapy (enhanced host conditioning) in a new Cohort C.
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference:
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 2024 with additional data available in mid-2024 – – Strong cash position of $140 million supports operations through 2025 – LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. “We are pleased with progress across the scientific field that continues to demonstrate the importance of neoantigens as the most attractive targets in solid-tumor oncology.
Achilles Therapeutics to Present at Upcoming Conferences
LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in June:
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 am PST. The event will be held at the Westin St. Francis Hotel in San Francisco, California.
Achilles Therapeutics: The First Full Position In My Tax Loss Selling Basket
ACHL has about $4.40 of cash per share on hand, yet it trades below $1. I believe that recent selling is due to tax loss sellers needing to recognize capital loss before the end of the year, and hence their selling is indiscriminate.
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy -
Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its participation in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 - 17, 2022. Iraj Ali, Chief Executive Officer, will present an overview of the company and pipeline on Tuesday, March 15, 2022, at 8:00 am ET / 12:00 pm UK.
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. ET.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ACHL.